The new managed markets paradigm: where should pharma sit?
eyeforpharma Ltd, headquartered at 7-9 Fashion Street, London, E1 6PX, United Kingdom. A registered company in England and Wales: 09823909. | Terms and conditions

Aidan Brain
VP Market Access | eyeforpharma
+44 (0)207 375 7513

Get the full PDF survey results sent directly to your inbox

The results are in – 100s of market access execs told us about their predictions for and frustrations with the development of managed markets in the US.

Download the results in full on the right ->

Here’s a taster of some of the more surprising results:
  • 48% said market access considerations still aren’t being considered till phase 2 of drug development
  • The shift towards specialty medicines no longer seems to be seen as a challenge
  • But clarity from payers is still the Holy Grail for market access Execs
The results also include feedback from such industry experts as:
  • Matt Portch, VP Managed Markets, Sunovion
  • John Cai, Director of Medical Informatics, Celgene
  • Stacy Woeppel, Deputy Director of Regulatory Affairs, Sanofi-Pasteur
  • Leonard M. Fromer, Executive Medical Director, Group Practice Forum
  • John Walker, Senior Strategic Advisor, The Kinetix Group
Get the PDF sent to your inbox ->

I look forward to hearing your thoughts!